These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 16117711

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The use of mutant mycobacteria as new vaccines to prevent tuberculosis.
    Hernàndez Pando R, Aguilar LD, Infante E, Cataldi A, Bigi F, Martin C, Gicquel B.
    Tuberculosis (Edinb); 2006; 86(3-4):203-10. PubMed ID: 16542875
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M, Shirakawa T.
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [Abstract] [Full Text] [Related]

  • 6. Current tuberculosis vaccine development.
    Young DB.
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S254-6. PubMed ID: 10875794
    [Abstract] [Full Text] [Related]

  • 7. Recent advances in improved tuberculosis vaccines.
    McMurray DN.
    Indian J Pediatr; 2000 Feb; 67(2 Suppl):S58-62. PubMed ID: 11129910
    [Abstract] [Full Text] [Related]

  • 8. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.
    Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, Mayner RE, Thole J, Walker KB, Liu M, Lambert PH, AERAS Global TB Vaccine Foundation, World Health Organization.
    Vaccine; 2005 May 31; 23(29):3753-61. PubMed ID: 15893612
    [Abstract] [Full Text] [Related]

  • 9. [Perspectives for new anti-tuberculous vaccines in the post-genomic era].
    García LF, Barrera LF.
    Biomedica; 2004 Jun 31; 24 Supp 1():228-38. PubMed ID: 15495589
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tuberculosis subunit vaccine design: the conflict of antigenicity and immunogenicity.
    Sable SB, Kalra M, Verma I, Khuller GK.
    Clin Immunol; 2007 Mar 31; 122(3):239-51. PubMed ID: 17208519
    [Abstract] [Full Text] [Related]

  • 15. Tuberculosis: vaccines in the pipeline.
    Ly LH, McMurray DN.
    Expert Rev Vaccines; 2008 Jul 31; 7(5):635-50. PubMed ID: 18564018
    [Abstract] [Full Text] [Related]

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 31; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 17. Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge.
    Vipond J, Vipond R, Allen-Vercoe E, Clark SO, Hatch GJ, Gooch KE, Bacon J, Hampshire T, Shuttleworth H, Minton NP, Blake K, Williams A, Marsh PD.
    Vaccine; 2006 Sep 11; 24(37-39):6340-50. PubMed ID: 16781800
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and protective efficacy of a DNA vaccine encoding the fusion protein of mycobacterium heat shock protein 65 (Hsp65) with human interleukin-2 against Mycobacterium tuberculosis in BALB/c mice.
    Wang LM, Bai YL, Shi CH, Gao H, Xue Y, Jiang H, Xu ZK.
    APMIS; 2008 Dec 11; 116(12):1071-81. PubMed ID: 19133010
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.